As a novel immune checkpoint receptor in T cells and NK cells, accumulating data support that targeting CD96 can improve the anti‐tumor immune response.[8, 10, 12, 18] We therefore examined whether blocking tumoral CD96 could improve cancer therapy in PDX models of immunocompromised mice (Figure 2A). This evidence concerns the gene CD96 and neoplasm.